Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Carl Beecroft

Podiatrist, Foot & Ankle Surgery Phoenix, AZ Doctor of Podiatric Medicine

NPI 1578564472 CMS profile 252508

15810 S 45Th St, Phoenix, AZ 85048

Open in the dashboard

General payments

$4,101

160 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Carl Beecroft of Phoenix, AZ is reported in the CMS Open Payments database as having received $4,101 across 160 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 62nd percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $537 21
2024 General $562 37
2023 General $383 14
2022 General $501 17
2021 General $500 25
2020 General $1,386 28
2019 General $232 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carl Beecroft
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Carl Beecroft were reported at $537. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Carl Beecroft Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $232 $389 $118–$1,406 $163
2020 $1,386 $191 $62–$691 $114
2021 $500 $329 $104–$1,341 $132
2022 $501 $419 $125–$1,611 $149
2023 $383 $377 $128–$1,164 $160
2024 $562 $394 $134–$1,168 $164
2025 $537 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Musculoskeletal Transplant Foundation Inc. $969 2 payments
  2. Organogenesis Inc. $572 34 payments
  3. Horizon Therapeutics plc $410 23 payments
  4. Stryker Corporation $313 6 payments
  5. Averitas Pharma Inc. $280 18 payments
  6. Smith+Nephew, Inc. $242 11 payments
  7. Djo, LLC $147 2 payments
  8. Amgen Inc. $130 7 payments
  9. ImpactOrtho, Inc. $127 1 payment
  10. Orthofix Medical, Inc. $100 14 payments
  11. Other $810 42 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,998 159 payments
  2. Education $103 1 payment
Products named General payments · program years 2019–2025
  1. KRYSTEXXA Krystexxa $391 22 payments
  2. Puraply $296 15 payments
  3. Qutenza $280 18 payments
  4. KRYSTEXXA Inflammation/Rare Disease $130 7 payments
  5. AUGMENT INJECTABLE $128 2 payments
  6. ORTHOLOC 2 LAPIFUSE $121 2 payments
  7. DR COMFORT $103 1 payment
  8. NUZYRA $78 5 payments
  9. Puraply Antimicrobial $76 3 payments
  10. FIXOS $71 1 payment
  11. Other $1,875 92 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

739

Median for Podiatry: 160

Drug cost

$10,413

Median for Podiatry: $2,368

Branded share of claims

17.9%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 140 $2,361
Terbinafine Hcl Generic 75 $1,940
Cyanocobalamin Injection Cyanocobalamin (Vitamin B-12) Brand 47 $1,684
Methylprednisolone Generic 139 $904
Doxycycline Monohydrate Generic 51 $544
Clindamycin Hcl Generic 35 $495
Duloxetine Hcl Generic 20 $441
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 11 $336
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 21 $300
Prednisone Generic 49 $267

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 71 billing codes

Paid by Medicare

$764,433

Of which drugs: $483,871

Medicare patients

511

Average age 76

Services billed

23,192

292 women, 219 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Diabetes 34%
Ischemic heart disease 33%
Chronic kidney disease 27%
Atrial fibrillation 22%
Depression 22%
Osteoporosis 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 17 40 $29

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qutenza
  • Averitas Pharma Inc. $197
$197 — —
KRYSTEXXA
  • Amgen Inc. $71
$71 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

160 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record